Received February 09, 2018; Accepted June 29, 2018; Published July 30, 2018
http://dx.doi.org/10.18081/2333-5106/018-223-235
Shu-Peng Zheng; Xiang Feng; Yi Liul
Abstract
Currently, there is little knowledge about transducin β-like protein 1 (TBL1) in tumor studies. Our previous studies reported immune cell-related TBL1 to be the key gene. Based on our searches of PubMed and the Web of Science, no studies have reported on the relationship between CTBL1 expression and the prognosis of PCa. Moreover, we have found certain signaling pathways that are significantly associated with CTBL1 in PCa. Little is known about the biological function of CTBL1 in PCa. Therefore, we decide to study the aberrant expression of CTBL1 and the relationship between CTBL1 and the signaling pathways in PCa. In the end, we will assess whether different CTBL1 expression is significantly associated with the prognosis of PCa. Biological function research and clinical feature associations could be superior evidence for the potential of TBL1 proteins to be potential targets for PCa therapy. Therefore, our study will provide a prospective research target for future studies on PCa. TBL1, identified as a component of the nuclear receptor corepressor (NCOR) complex, has been found to have the ability to regulate histone modification as well as gene transcription. Dysfunction of TBL1 is closely related to the occurrence and progression of human solid malignancy. Although TBL1 plays a crucial role in the development of some immune disorders and tumors, the biological role of cytoplasmic transducin β-like related protein 1 (CTBL1) remains unknown. A retrospective analysis of medical records was systematically conducted to uncover the functions of CTBL1 in malignant tumors and other diseases. Pathological and clinical records provided us with an unprecedented opportunity to explore the significance of CTBL1 in level posed tissue microarray (TMA). CTBL1 was over-expressed in PCa tissues by analyzing gene expression datasets.
Keywords: Prostate cancer; Androgen receptor; TBLR1; Real-time PCR
References
1. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, Wong J: Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J 2003; 22(6):1336-1346. [PubMed]
2. American Cancer Society (2013) Prostate Cancer.
3. European Commission Eurostat (2013) European shortlist of causes of death.
4. Herrmann C, Cerny T, Savidan A, et al. Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer 2013;13: 287. [PubMed]
5. Breslow N, Day N (1987) Statistical methods in cancer research. Volume II – The design and analysis of cohort studies. 406 p.
6. Wallner LP, Wang R, Jacobsen SJ, Haque R. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. Cancer Epidemiol Biomarkers Prev 2013; 22: 313–316. [PubMed]
7. Alhasani S, Yousif NG. Critical role of IL-23 signaling in prostatic cancer. American Journal of BioMedicine 2013; 1(1):4-6. [Abstract/Full-Text]
8. Garrett D. TBLR1, an androgen receptor coactivator, regulates prostate cancer growth.Ph.D. Thesis, NEW YORK UNIVERSITY, 2013, 188 pages; 3591189 [Abstract]
9. Choi HK, Choi KC, Yoo JY, et al. Reversible SUMOylation of TBL1-TBLR1 regulates beta-catenin-mediated Wnt signaling. Mol Cell 2011; 43(2):203-216. [Full Text]
10. Nash GF, Turner KJ, Hickish T, et al. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl 2012; 94: 456–462. [PubMed]
11. Li J, Wang CY: TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nature Cell Biol 2008; 10(2):160-169. [Full Text]
12. Kulozik P, Jones A, Mattijssen F, et al. Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab 2011; 13(4):389-400. [Full Text]
13. Sharma D and Fondell JD. Ordered recruitment of histone acetyltransferases and the TRAP/mediator complex to thyroid hormone‐responsive promoters in vivo. Proc Natl Acad Sci USA 2002; 99: 7934–7939. [ Abstract/FREE Full Text]
14. Wong J, Shi YB and Wolffe AP (1995) A role for nucleosome assembly in both silencing and activation of the Xenopus TRβA gene by the thyroid hormone receptor. Genes De 1995; 9:2696–711. [Abstract/FREE Full Text]
15. Van Hemelrijck M, Drevin L, Holmberg L. et al. Primary cancers before and after prostate cancer diagnosis. Cancer 2012; 118: 6207–6216. [PubMed]
16. Murray L, Henry A, Hoskin P, et al.. (2014) Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique. Radiother Oncol.
